Cancer Immunology Research

Papers
(The median citation count of Cancer Immunology Research is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
A Sampling of Highlights from the Literature166
Abstract A022: Therapeutic inhibition of TREX1 elicits type I interferon–mediated antitumor immunity with minimal autoimmune toxicity115
Abstract A018: Targeting PTPN1/PTPN2 with KQ-791 enhances NK cell cytotoxicity during tumor rechallenge108
Abstract B002: Meta-Analysis of Neoantigens: Insights from the Cancer Epitope Database and Analysis Resource (CEDAR)105
Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade89
Host Interactions with Engineered T-cell Micropharmacies83
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions79
Correction: Inflammation Mediated by Gut Microbiome Promotes Immune Suppression and Lung Adenocarcinoma Progression73
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy73
Abstract LB-C008: Replication stress coupled to cGAS–STING activation defines an innate immune–inflamed transcriptional state in head and neck squamous cell carcinoma that Is enriched for HPV-positive71
Abstract LB-C012: Immune-Like Circulating Tumor Cells and Large Extracellular Vesicles in Metastatic Breast Cancer59
Abstract LB-A013: Tuning TCR immunotherapy targeting prostatic acid phosphatase via catch bond modifications for advanced prostate cancer57
Abstract LB-C011: Using Organoids and Tumor Infiltrating Lymphocytes to Elucidate the ”Dark Matter” of Human Tumor Antigens55
Abstract LB-A006: Impact of pharmacokinetic profiles on the in vivo antitumor efficacy of EHMT2 inhibitors combined with immune checkpoint blockade55
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer55
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types54
Transforming the Dark into Light: A Siglec-9 Switch53
IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer52
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity52
Abstract A046: Dendritic cell dysfunction predicts adverse prognosis in high-risk acute lymphoblastic leukemia51
Abstract A028: Combination therapy with a TCR Vβ-directed bifunctional molecule, cisplatin and anti-PD-1 promotes antitumor activity in immune checkpoint blockade-refractory head and neck murine tumor49
Abstract A041: LAG-3 is associated with poor prognosis and LAG-3 blockade enhances the efficacy of PD-1 blockade combined with radiation therapy in breast cancer49
Abstract C070: Targeting neoantigens conserved across organs and species overcomes tumor immune escape48
Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment47
Abstract B035: Antibody-lectin chimeras for glyco-immune checkpoint blockade47
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies46
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer44
The ω-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid Enhances NK-Cell Antitumor Effector Functions44
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors43
T-cell Senescence in the Tumor Microenvironment42
A Sampling of Highlights from the Literature42
IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma42
Engineering CD20 CARs with a Twist42
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens42
A Sampling of Highlights from the Literature41
Evaluation of Proton Minibeam Radiotherapy on Antitumor Immune Responses in a Rat Model of Glioblastoma39
Circulating Neoantigen- and Viral Oncoprotein–Specific CD8+ T Cells Share a Transcriptional Signature37
Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers37
Profiling Multiple CD8+ T-cell Functional Dimensions Enhances Breast Cancer Immune Assessment35
Ethnicity, Immunity, and Outcomes: Biology versus Socioeconomic Status34
A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor34
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment34
CLK1 Promotes Myeloid-Derived Suppressor Cell Trafficking and Reprograms the Tumor Microenvironment by Activating Hippo/YAP Signaling in Colorectal Cancer34
Identification and Phenotypic Characterization of Neoantigen-Specific Cytotoxic CD4+ T Cells in Endometrial Cancer34
KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer34
High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects33
Ncoa2 Promotes CD8+ T cell–Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α Critical for Mitochondrial Function33
Antibody-Mediated Inhibition of HLA/LILR Interactions Breaks Innate Immune Tolerance and Induces Antitumor Immunity32
Cancer cell–intrinsic SSBP4 enables tumor immune evasion by promoting cholesterol biosynthesis32
Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes32
Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells31
Abstract LB-B005: No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S140430
Abstract LB-B013: Eight-Pathway transcriptomic biomarker outperforms PD-L1 for anti-PD-1 response prediction in melanoma29
Abstract A042: Onco-fetal immune tolerance factors shape T cell exhaustion and immune evasion in pregnancy and cancer28
Abstract B058: Longitudinal single cell and TCRβ profiling of a melanoma patient during adjuvant immune checkpoint inhibitor therapy exhibits significant change in immune cell profiles28
Abstract C032: Comparison of genomic drivers and transcriptomic features of immunogenicity in pancreatic malignancies28
Abstract B024: The clinical benefit from treatment of advanced MSS mCRC with the adenosine 2a/2b antagonist etrumadenant is associated with adenosine-mediated T-cell exclusion and enhancement of the e28
Abstract A062: Endometriosis as a Neuroimmune Disorder: Integrating Inflammation, Innervation, and Sensitization28
Abstract A074: Immune dysregulation and B-cell fitness driven by PLCγ2 R665W: Insights from a novel conditional B-cell mouse model27
Abstract A061: First-in-human hapten-enhanced stressed-ghost cell immunotherapy (STC-1010) for advanced colorectal cancer: preclinical and early clinical data27
Abstract A031: Systemic Inflammatory Biomarkers and Lu-177-PSMA Radiopharmaceutical Therapy Response in Sipuleucel-T-Pretreated Metastatic Castration-Resistant Prostate Cancer27
Abstract B005: Harnessing GD2-CAR macrophages to target high-risk neuroblastoma27
Abstract A075: Molecular glues activate immunoproteasomes to amplify and expand the MHC-class-I immunopeptidome that promotes TCR-engineered T-cell cytotoxic activity against multiple myeloma27
Abstract C066: Matrix-M adjuvant – A promising adjuvant for preventative and therapeutic cancer vaccines development26
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity26
Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses26
Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer26
Abstract C021: Cryo-Immune Vaccination (CIV): A locoregional device/multidrug immunotherapeutic approach that can bypass toxicity yet systemically eradicate metastatic cancers25
A Sampling of Highlights from the Literature25
Abstract B074: Killing cancer cells by suicidal bombing attack with neutrophil extracellular traps25
Abstract B018: Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy25
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission25
FOXM1-Specific TCR-Engineered T Cells Target Non–Small Cell Lung Cancer25
About the Rising Star25
SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma25
Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC After Immune Checkpoint Blockade24
Abstract A045: Overcoming platelet-mediated immune suppression in ovarian cancer24
Abstract C062: Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth24
Pseudomonas aeruginosa Exacerbates Bladder Cancer Progression by Activating Cancer-Driven Immunosuppression24
Abstract A012: Cancer acquires therapy resistance by converting immune infiltration to exclusion through NK cell-macrophage interactions23
Acknowledgment to Reviewers23
PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation23
CCRL2 Expression by Specialized Lung Capillary Endothelial Cells Controls NK-cell Homing in Lung Cancer23
Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses22
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma22
In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade22
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma22
Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry22
Spatial Organization of Macrophages in CTL-Rich Hepatocellular Carcinoma Influences CTL Antitumor Activity22
Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells22
ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion21
TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer21
Abstract PR-05: Sumoylation blockade exposes the dark epigenome to drive ZBP1 viral mimicry for cancer immunotherapy21
A Sampling of Highlights from the Literature21
Abstract A040: Measurement of CD8+ T cell-mediated anti-tumor immune response induced by neoadjuvant chemo-radiation therapy using T-cell receptor analysis in rectal cancer patient20
Targeting LxCxE Cleft Pocket of Retinoblastoma Protein in Immunosuppressive Macrophages Inhibits Ovarian Cancer Progression20
Abstract LB-C004: Epigenetic immune reprogramming overcomes PD-1 resistance in metastatic melanoma patients: the phase II NIBIT-ML1 study20
IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells20
Abstract C046: High-throughput phenotypic screening reveals novel immunomodulators that enhance immunotherapy in high-risk neuroblastoma20
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors19
Abstract LB-A008: Reversing immune checkpoint inhibitor resistance rherapy in advanced thyroid cancer19
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies19
Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells19
Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade19
Determinants for Antitumor and Protumor Effects of Programmed Cell Death18
IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma18
Reprogramming CD8+ T-cell Branched N- Glycosylation Limits Exhaustion, Enhancing Cytotoxicity and Tumor Killing18
Translating Science into Survival: Report on the Seventh International Cancer Immunotherapy Conference18
The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling18
Battle Within the Sexes: Differences in Male and Female Immunity and the Impact on Antitumor Responses18
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy18
Atypical B Cells Promote Cancer Progression and Poor Response to Bacillus Calmette-Guérin in Non–Muscle Invasive Bladder Cancer18
Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN18
CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression18
A Sampling of Highlights from the Literature17
Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells17
Abstract A011: IL-12 armored anti-macrophage CAR T cells reset and reprogram the tumor microenvironment to control metastatic ovarian and lung tumor growth17
CD8+ T Cells Keep Their (K+)urrency for Function17
Abstract B003: Oncolytic VSVd51-LIGHT and folfirinox chemotherapy increases anti-tumor immune response in pancreatic ductal adenocarcinoma17
Abstract A043: Single-cell and bulk transcriptomics uncovers GATA3-mediated macrophage immunosuppressive programming in murine and human cancers17
A Sampling of Highlights from the Literature17
Single-Cell Clonal Lineage Tracing Identifies the Transcriptional Program Controlling the Cell-Fate Decisions by Neoantigen-Specific CD8+ T Cells17
Abstract B011: Mast cells mediate tumor-suppressive effects in head and neck cancer through immune-microenvironmental regulation17
Abstract B070: Fc-optimized GITR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote anti-tumor immunity17
MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming16
Abstract LB-A002: Open-label, Phase Ib dose-expansion study assessing the efficacy of the CD137/FAP agonist BI 765179 plus pembrolizumab as first-line therapy in metastatic or incurable, recurrent PD-16
Pan-Cancer Single-Cell RNA Sequencing Analysis Refines Multi-Origin Monocyte and Macrophage Lineages16
Regulatory Considerations for Genome-Edited T-cell Therapies16
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells16
Antitumor Immune Responses in B2M -Deficient Cancers16
Cancer Immunology Research: A Decade of Illumination and Innovation16
A Metabolic Axis of Immune Intractability16
Tumor-derived complement C3 overexpression in STK11-mutant lung adenocarcinoma drives tumor growth and immune checkpoint inhibitor resistance16
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors16
Abstract LB-B006: A Phase II chemo/immunotherapy study using metronomic gemcitabine, doxorubicin, docetaxel and nivolumab for advanced angiosarcoma (NCT04535713): An interim analysis16
Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma16
The PO4-tential for Less Toxic CAR T-cell Therapies15
Constitutive STAT3 Signaling, in Comparison with STAT5, Enhances CAR T-cell Efficacy and Lowers Systemic Toxicity15
A Sampling of Highlights from the Literature15
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors15
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target15
Abstract C020: Spatial and molecular landscape in clear cell renal cell carcinoma bone metastatic patients14
Abstract IA03: Therapeutic modulation of nucleic acids-induced immune activation14
Abstract A066: MMR-stratified spatial programs of normal and cancer-associated fibroblasts and their association with lymphocyte pervasiveness in CRC14
CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma14
Abstract A065: Fast and cost-effective prediction of treatment response in head and neck cancer by characterizing the tumor microenvironment from routine H&E slides14
Abstract B022: Investigating Biased GPCRs Activation by Nutraceutical Caffeine and Nicotine in Transactivating Glycosylated Receptors to Induce EMT in Cancer Metastasis14
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors14
Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy14
Abstract A005: Utility of an oncogene-driven spontaneous triple-negative breast cancer model for immunotherapeutic testing14
Abstract B002: A LIBRARY OF POTENT TCRS DERIVED FROM HEALTHY DONORS TARGETING KRAS G12D AND G12V NEOANTIGENS13
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation13
Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy13
Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function13
Abstract C005: Understanding the Role of Tonic TCR Signaling to Optimize CAR-T Efficacy13
Abstract C057: Tankyrase Inhibition Reprograms Melanoma Metastases to Overcome Resistance to PD-1 Blockade13
The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides13
Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors13
Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts13
Abstract B064: Association of different TP53 mutation subtypes with the efficacy of first-line immunotherapy in locally advanced and metastatic lung squamous cell carcinoma13
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer13
A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy13
TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer13
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models12
Abstract LB-C010: Flare: A clinical stage platform designed to overcome challenges of the tumor microenvironment and universally target tumors of epithelial origin12
Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ–IRF1–SREBF2 Axis12
Abstract B007: Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy12
Abstract LB-C006: Scalable TCR synthesis and screening enable antigen reactivity mapping12
Abstract A049: CD8+ T cell decline from regression to recurrence in ovarian cancer is linked to expansion of suppressive macrophages12
The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Effi12
Antigen Priming Induces Functional Reprogramming in iNKT Cells via Metabolic and Epigenetic Regulation: An Insight into iNKT Cell-Based Antitumor Immunotherapy12
CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation12
Abstract B075: Innate lymphoid cell reprogramming reveals immunometabolic and epigenetic signatures following checkpoint blockade in head and neck squamous cell carcinoma (HNSCC)12
Abstract IA04: Reprogramming the tumor–immune microenvironment: From stromal circuits to engineered microbial immunotherapies12
The CCL17–CCR4 Axis Is Critical for Mutant STAT6-Mediated Microenvironmental Remodeling and Therapeutic Resistance in Relapsed/Refractory Diffuse Large B-Cell Lymphoma12
A Sampling of Highlights from the Literature12
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer12
Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function11
Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma11
Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway11
TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment11
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma11
Abstract A051: Integrative Single-Cell and Spatial Transcriptomics Reveal Metabolic Reprogramming and Spatiotemporal Transition of Macrophages Driving Immune Suppression in Head and Neck Cancer11
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade11
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells11
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain11
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer11
Upregulation of an Epithelial miRNA Is Associated with Immune Evasion in Progressive Bronchial Premalignant Lesions11
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory11
PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy11
Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses11
Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma11
Combination of Anti–PD-1 and Electroacupuncture Induces a Potent Antitumor Immune Response in Microsatellite-Stable Colorectal Cancer11
Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM10
Abstract C023: Tertiary lymphoid structures generate anti-tumor immunity independently of immune responses in secondary lymphoid organs upon STING and lymphotoxin-β receptor activation10
Abstract C051: Genomic and spatial immune biomarkers predictive of chemoimmunotherapy response in triple-negative breast cancer10
Abstract A015: The emerging role of basophils in non-muscle-invasive bladder cancer10
CD49a Targeting Enhances NK Cell Function and Antitumor Immunity10
Unlocking the Immune Response in ALK-Rearranged Lung Adenocarcinoma10
Abstract A004: A minimal gene panel approach for cost-effective identification of tumor-reactive T cells10
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors10
Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice10
About the Rising Star10
Abstract B025: Anti-GD2 combined with anti-PD1 enhances tumor immunity with T cell memory via inducing immunogenic cell death10
Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1+ Gastric Cancer10
Abstract A005: TAZ-TEAD signaling alters the immune microenvironment of cutaneous melanoma10
Abstract IA04: Investigating T cell immunobiology using genetically engineered models10
Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer9
The Problem with Syngeneic Mouse Tumor Models9
The Dark Knight: Functional Reprogramming of Neutrophils in the Pathogenesis of Colitis-Associated Cancer9
Abstract PR-15: Neuroimmune dysregulation in ovarian cancer: the role of chronic stress on microglial activation and systemic inflammation9
Abstract C044: Analysis of 1000 secreted proteins in functional genomics and compound screens reveals cytotoxic and immunomodulatory targets9
Abstract A017: Neutrophil extracellular traps reprogram macrophages to an immunosuppressive phenotype in non-small-cell lung cancer9
A Sampling of Highlights from the Literature9
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids9
Chronic ISG15 Exposure Accelerates CD8+ T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma9
Abstract IA08: Development and use of Engineered Regulatory T cells to treat Autoimmune Diseases9
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors9
Abstract A072: The T cell precursor frequency determines the immunogenicity of cancer neoantigens9
Abstract A023: Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression9
The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy9
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer9
Abstract A006: Assessment of EBV DNA methylation to guide antiviral use in EBV-associated lymphoma9
Abstract B027: iSIGN panel identifies germ cell tumors via whole-proteome phage immunoprecipitation sequencing9
Abstract B036: Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab9
Abstract C008: NFIL3 emerges as a driver of CAR T cell dysfunction from integrated in vivo/in vitro CRISPR screen9
A Sampling of Highlights from the Literature9
Gastric Microbiome Alterations Are Associated with Decreased CD8+ Tissue-Resident Memory T Cells in the Tumor Microenvironment of Gastric Cancer8
Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome8
Interactions between MDSCs and the Autonomic Nervous System: Opportunities and Challenges in Cancer Neuroscience8
Tumor Cell–Intrinsic c-Myb Upregulation Stimulates Antitumor Immunity in a Murine Colorectal Cancer Model8
Abstract A003: Identification of immunomodulatory compounds by high-throughput proteomics: Insights from quantification of 1000 proteins in a 20,000 sample screen8
Abstract A004: Modulating chromatin remodeling as a strategy to reverse immune evasion in ovarian cancer8
The FcγRIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell–Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing8
High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance8
iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-cell RNA-Seq Data and Differentiate Cell Type–Specific Markers of Immune-Cell Infiltration8
Abstract LB-B012: Signals from the tumor immune microenvironment induce a potent immune modulatory gene expression program in senescent breast tumor cells8
Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity8
Abstract B004: Route dependent T-cell activation by mRNA cluster therapies8
FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors8
Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer8
Tyrosine Kinase Inhibition Activates Intratumoral γδ T Cells in Gastrointestinal Stromal Tumor8
Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands8
Abstract B021: Multi-functional telodendrimer nanodrug: Nanocarrier for ovarian cancer treatment and immunomodulator to control inflammation and sensitize the tumor8
Abstract PR-12: Single-cell profiling of tumor-infiltrating B cells reveals autoantibody repertoires and potential cross-talk with T cells8
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors8
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity7
The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy7
Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN50547
Abstract C007: A versatile microRNA-based platform for activation-dependent regulation of armored CAR T cell payloads7
0.10345196723938